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Abstract. The ability to regulate proteolytic functions 
is critical to cell biology. We describe eveiats that regu- 
late the initiation of the coagulation cascade on endo- 
thelial cell surfaces. The transmembrane protease re- 
ceptor tissue factor (TF) triggers coagulation by 
forming an enzymatic complex with the serine protease 
factor VIIa (VIIa) that activates substrate factor X to 
the protease factor Xa (Xa). Feedback inhibition of the 
TF.VIIa enzymatic complex is achieved by the forma- 
tion of a quaternary complex of TF.VIIa, Xa, and the 
Kunitz-type inhibitor tissue factor pathway inhibitor 
(TFPI). Concomitant with the downregulation of 
TF.VIIa function on endothelial cells, we demonstrate 
by immunogold EM that TF redistributes to caveolae. 
Consistently, TF translocates from the Triton X-100- 
soluble membrane fractions to low-density, detergent- 
insoluble microdomains that inefficiently  support 
TF.VIIa proteolytic function. Downregulation of 
TF.VIIa function is dependent on quaternary complex 
formation with TFPI that is detected predominantly in 
detergent-insoluble microdomains. Partitioning of 
TFPI into low-density fractions results from the associ- 
ation of the inhibitor with glycosyl phosphatidylinosi- 
tol-anchored binding sites on external membranes. 
Free Xa is not efficiently  bound by cell-associated 
TFPI; hence, we propose that the transient ternary 
complex of TF.VIIa with Xa supports translocation and 
assembly with TFPI in glycosphingolipid-rich micro- 
domains. The redistribution of TF provides evidence 
for an assembly-dependent translocation of the inhib- 
ited TF initiation complex into caveolae, thus implicat- 
ing caveolae in the regulation of cell surface proteolytic 
activity. 
C 
ELLS accomplish tasks of invasion, migration, tissue 
remodeling and cell-cell communication in part 
through the regulated expression of cell-associated 
protease systems. Cell surface protease cascades  are trig- 
gered by the upregulation of protease receptors, such as 
the urokinase receptor of the fibrinolytic system (14) and 
tissue  factor (TF)  1 that initiates the plasma coagulation 
pathways (48). Based on structural homology in the extra- 
cellular domain, TF is classified as a member of the cyto- 
kine receptor family and most closely related to the inter- 
feron and IL-10  receptors  (48). However, in contrast to 
the four helix bundle ligands  of the latter, TF binds  the 
multidomain serine protease factor VIIa (VIIa) with sub- 
nanomolar affinity. The assembly of the protease into the 
TF-VIIa  complex  results  in  markedly  enhanced  pro- 
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teolytic activation of the substrates factor X and factor IX. 
The product protease factor Xa (Xa) activates  prothrom- 
bin to thrombin that converts fibrinogen into an adhesive 
fibrin matrix as well as elicits diverse  cellular  responses 
through the signaling thrombin receptor (63). 
The TF-driven coagulation pathway is regulated by spe- 
cific inhibitors,  i.e., the serine protease inhibitor (serpin) 
antithrombin III and the Kunitz-type inhibitor tissue fac- 
tor pathway inhibitor (TFPI) (6, 41). Both inhibitors are 
present in plasma, but the latter is also found on endothe- 
lial cells, the major biosynthetic source for TFPI (1). TFPI 
inhibits the TF.VIIa complex most efficiently in the pres- 
ence of Xa (7). The second Kunitz-type domain of TFPI 
binds and inhibits Xa, and complex formation of TFPI with 
Xa is thought to facilitate the assembly of the first Kunitz- 
type domain with VIIa when bound to TF (6). This results 
in a stable quaternary complex characterized by slow dis- 
sociation. The third Kunitz-domain and the basic carboxyl 
terminus of TFPI are implicated in the binding of glycosami- 
noglycans (15, 66), which are inferred to be expressed  on 
vascular endothelial cells (53). The binding site and the cel- 
lular localization of TFPI on endothelial cells are not estab- 
lished. 
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unless stimulated by cytokines, such as tumor necrosis fac- 
tor oL (TNFa) (37). In most cell types, TF is predominantly 
expressed on the cell surface and accessible to functional 
inhibition by mAbs (12). Expression of TF was observed 
on the basolateral side of endothelial cells after stimula- 
tion in vitro (33); this pattern is consistent with expression 
of TF on cellular processes or membrane ruffles documented 
for fibroblasts  (8),  certain tumor cells  (34),  and macro- 
phages (22). Other studies documented expression of TF 
predominantly on the apical side of endothelial cells (25, 
35), and this restricted display was attributed to the forma- 
tion  of tight junctions  between  endothelial  cells  in  the 
monolayer (35). Endothelial cell expression of TF in vivo 
was demonstrated in the spleen of septic animals (13) and 
in the tumor vasculature (11). Regulation of TF function is 
thus  considered  critical  to  maintain  the  anticoagulant 
properties of the vascular endothelium in vivo. 
We here characterize the regulation of cell surface pro- 
teolytic function of the TF.VIIa complex on endothelial 
cells and find that the downregulation of TF function is ac- 
companied by a translocation of TF into noncoated plas- 
malemma vesicles (caveolae). Caveolae are morphologi- 
cally defined small plasmalemma vesicles characterized by 
the presence of the marker protein caveolin, a structural 
component of the  vesicles (44).  Caveolae have  a  mem- 
brane composition that is rich in glycosphingolipids and 
cholesterol, resulting in decreased solubility in certain de- 
tergents. Caveolae were first described as a transport sys- 
tem mediating transcytosis across endothelial cells (38, 55) 
and play a role in the uptake (potocytosis) of certain small 
molecules that is mediated by glycosyl phosphatidylinosi- 
tol (GPI)-linked receptors (2). Molecules involved in the 
signal transduction pathways have been shown to be en- 
riched in glycosphingolipid-rich microdomains of cellular 
membranes, further suggesting a regulatory role of caveo- 
lae in signal transduction (17, 54). In this study, we demon- 
strate that downregulation of TF-initiated proteolytic fun- 
ction is associated with receptor translocation into caveolae. 
This inhibition of TF function is mediated by cell-associ- 
ated TFPI, and we elucidate critical interactions that are 
required for assembly of the TF.VIIa complex with TFPI. 
This study provides insight into the control of cellular pro- 
teolytic functions that is mediated by the redistribution of 
the inhibited TF.VIIa initiation complex to caveolae. 
Materials and Methods 
Reagents 
The mAbs to TF factor X and VIIa had been characterized and were puri- 
fied from ascites on immobilized protein A  as described (50). Polyclonal 
antibodies to TFPI were generated in rabbits and purified as described 
(64),  and mAbs to the first (4903)  or second (4904)  Kunitz domain of 
TFPI were purchased from American Diagnostica Inc. (Greenwich, CT). 
The mAb to caveolin (anti-22-kD Rous Sarcoma Virus-Src substrate) was 
obtained from ICN Biomedicals Inc. (Irvine, CA). HRP-conjugated sec- 
ondary antibodies and reagents for chemiluminescence detection were 
from Amersham Life Science (Arlington Heights, IL). Secondary gold- 
conjugated antibodies were from BBI International  (Cardiff,  UK). Re- 
combinant VIIa was expressed in CHO cells and purified as described 
(46). Factor X was purified from plasma as described (49). Human Xa in- 
activated  with  glutamyl-glycyl-arginyl-chloromethyl ketone  (EGR-Xa) 
and unmodified Xa were purchased from Haematologic Technologies Inc. 
(Essex Junction, VT). 
Cell Culture 
The spontaneously transformed human umbilical vein endothelial cell line 
ECV304 was obtained from the American Type Culture Collection (Rock- 
ville, MD) (ATCC CRL-1998) and was grown as monolayer in media 199 
supplemented with  10%  FBS  and 2  mM glutamine. Before  all  experi- 
ments, confluent ECV304 cell monolayers were stimulated for 5 h with 10 ng/ 
ml recombinant TNFc~ (Cetus Corp., Emeryville, CA) to induce maximal 
TF  expression. Stimulation  with  TNFct  consistently resulted  in  an  in- 
creased expression of TF based on immunochemical  detection by Western 
blot analysis of fracionated cell lysates or by quantitative immunoassay  of 
whole cell lysates (see below).  All incubations and washes were carried 
out in cell buffer (21  mM Hepes, 137  mM NaCI, 5 mM KCI, 0.75 mM 
Na2HPO4, 5.5 mM glucose, 2 mM CaCI2, pH 7.4), unless otherwise noted. 
ELISA 
TF  concentration  of ECV304  cells was  determined by  an  mAb-based 
sandwich ELISA, as described previously in detail (52). Cells were lysed 
in 6 mM CHAPS before dilution in assay buffer. The capture antibody was 
TF9-6B4,  and the detection antibody was biotinylated TFS-SG9. These 
mAbs are directed to nonoverlapping epitopes on TF (50). Bound second- 
ary antibody was detected using streptavidin-conjugated HRP and tetra- 
methylbenzidine as substrate. The concentration of TFPI in ECV304 ly- 
sates was determined by a  commercially available immunoassay that is 
based on a polyclonal capture antibody and a monoclonal detection anti- 
body (IMUBIND  Total TFPI ELISA Kit; American Diagnostica Inc.). 
Cell pellets were lysed in 50 mM CHAPS and serially diluted in the sam- 
ple  dilution buffer recommended by  the manufacturer. Mean  and  SD 
were calculated for cell pellets that were harvested on different occasions. 
Determination of TFPI Concentration by 
Functional Assay 
Cells were lysed in 15 mM octylglucopyranoside and diluted fivefold in 
buffer containing 5  mM octylglucopyranoside. TFPI  activity was mea- 
sured in a two-stage end-point chromogenic assay. First, test samples were 
incubated with a  reaction mixture containing a  limited concentration of 
VIIa (0.5 ng/ml), relipidated TF (10 ng/ml), Xa (5 ng/ml), and CaCI2 (10 mM) 
in 60 ixl for 30 min at room temperature. Then, 100 pA of a mixture of fac- 
tor X  (2.5/.~g/ml), CaC12, and Chromozym X  (1.25  mg/ml) was added to 
the reaction. After 20 min, absorbance at 405 nm was measured. The con- 
centrations of TFPI in the samples were calculated from a standard curve 
of purified recombinant TFPI diluted in 5 mM octylglucopyranoside. 
Assay for Cell Surface Proteolytic  Activity of TF.VIIa 
Stimulated ECV304 cells in 24-well tissue-culture plates were washed and 
incubated with 10 nM VIIa in cell buffer for 60 min at 4°C. Dose titration 
of Vlla in preliminary experiments established that this concentration of 
VIIa was sufficient to saturate TF on stimulated ECV304, consistent with 
the findings on other cell  types (29).  After washes in cell  buffer (see 
above), cells were warmed to 37°C for 10 min before the addition of 5 p,M 
substrate factor X  (in a  total volume of 0.5 ml). Samples (50 ixl) were 
taken during a 30-min incubation time and quenched in 150 p,1 of i00 mM 
EDTA. The amount of Xa generated at each time was determined from 
the hydrolysis of the chromogenic substrate Spectrozyme FXa (American 
Diagnostica Inc.) added to the quenched reaction (52). Rates of Xa gener- 
ation were calculated from the increase in product between two consecu- 
tive time points. In antibody blocking experiments, 100 p,g/ml polyclonal 
anti-TFPI IgG was included in the preincubation with Vlla (5 riM) at 37~C 
for 30 min followed by the addition of substrate factor X  (500 riM) (all 
concentrations are based on  the final reaction volume).  Samples were 
taken as above for determination of the rate of Xa generation. 
Electron Microscopy 
After experimental treatment and antibody staining, cells were fixed in 
modified Karnovsky's fixative (2%  paraformaldehyde, 1.5%  glutaralde- 
hyde in 0.1 M cacodylate buffer, pH 7.4) for 1-2 h at 4°C and postfixed in 
1% OsO4 for 1 h at room temperature. The fixed cells were stained (en 
block) in 1% aqueous uranyl acetate, dehydrated in graded ethanol, and 
embedded in TAAB 812 epoxy resin (TAAB Laboratories Equipment, 
Reading, Berks, UK). Thin sections were cut parallel to the dish to yield 
an en face view. For the purpose of counting gold granules on vertical sec- 
tions, two pieces of cell-bearing epon sheets were sandwiched, with cell 
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larly sectioned cells. These sections were mounted on a Pelco 100-bar grid 
with 285-~m intervals (Ted Pella, Inc., Irvine, CA). Thin sections were 
stained in uranyl acetate and lead citrate and viewed with an electron mi- 
croscope (HU 12A; Hitachi Ltd., Tokyo, Japan). 
The conditions for the specific experiments were as follows: (a) local- 
ization of TF by indirect immunogold detection: stimulated ECV304 cells 
were washed and incubated with 30 ixg/ml TF9-10H10 IgG with or without 
5  nM Vfla  and 200 nM factor X  for 30 rain at  37°C. Cells were  then 
washed and incubated with goat anti-mouse IgG 10-nm gold conjugate for 
30 min at 4°C followed by washes before fixation. (b) Quantitation of TF 
translocation with directly labeled anti-TF Fab fragments: Fab fragments 
of TF9-10H10 were generated by papain digestion of IgG and monovalent 
protein was purified to homogeneity by ion exchange chromatography as 
described (51).  A  gold colloid with an average size of <5 nm was pro- 
duced by the reduction of tetrachloroauric acid with sodium borohydrid 
(62). To 50 ml of 0.01% chloroauric acid, a freshly prepared 0.1 M sodium 
borohydrid solution was added drop by drop in a  rapid succession until 
the color turned reddish orange. The colloidal gold particles were com- 
plexed with TF9-10H10 Fab in deionized water according to the method 
of Geoghegan and Ackerman (19). Stimulated ECV304 cells were washed 
and incubated with TF9-10H10 Fab gold conjugate (30 ~g/ml) without 
(control) or with 10 nM VIIa for 1 h  at 4°C. Cells were washed rapidly 
three times and incubated without (control) or with 200 nM factor X for 
15 rain at 37°C. After rapid washes with ice-cold buffer, cells were imme- 
diately fixed at 4°C. 
Separation  of Trition X-lOO-4nsoluble Complexes by 
Sucrose Gradient  Ultracentrifugation 
The protocol described by Lisanti et al. (31) was used with the following 
specific experimental conditions: ECV304 cells were grown to confluence 
for 3 d  in 150-cm  2 flasks and stimulated for 5 h  with TNFet. Cells were 
washed and incubated with or without 5 nM Vfla in cell buffer for 1 h at 
4°C. For blocking experiments, inhibitory polyclonal anti-TFP1 antibody 
was included at 30 I~g/ml during this preincubation step. The supernatant 
was removed, and the cells were incubated for an additional- 15 rain at 
37°C with cell buffer alone or cell buffer containing either 200 nM factor X, 
5 nM Xa, or 5 nM EGR-Xa. For the blocking experiment with anti-TFPI 
antibody, 200 nM factor X  and 30 ~g/ml polyclonal anti-TFPI were in- 
cluded during the latter incubation. Cells were then washed with ice-cold 
cell buffer followed by cell buffer with lower CaC12 (0.5 mM) to reduce  e 
the amount of proteins (Vlla, factor X, Xa) that were nonspecifically as- 
soeiated with cell membranes through their "v-carboxyglutamic acid-rich 
domains. All subsequent steps were carried out at 4°C. The ceils were har- 
vested by scraping in low CaCI2 cell buffer, and a cell pellet was obtained 
by centrifugation at 200 g. The pellet was resuspended in 2 ml of MES- 
buffered saline (25 mM MES, 150 mM NaCI, pH 6.5) containing 1% Triton 
X-100, 1 mM NaVO4, 1 mM PMSF, and 100 I~M CaCI2. Cells were homog- 
enized with 10 strokes in a loose-fitting dounce homogenizer, and then su- 
crose was added to 40%. Homogenates were placed at the bottom of an 
ultracentrifuge tube, and a 30-5% sucrose gradient in MES-buffered sa- 
line containing 1 mM NaVO4, 1 mM PMSF, and 100 ~M CaClz, but no Tri- 
ton X-100, was placed on top. The gradient was centrifuged at 39,000 rpm 
in a rotor (SW40Ti; Beckman Instruments, Fullerton, CA) for 16-20 h at 
4°C. Gradients were collected in eight 1.5-ml fractions from the top. Frac- 
tions 1-6 contain material floating in the sucrose gradient, whereas frac- 
tion 7 included the 30/40% sucrose interface, and fraction 8 contained the 
remaining Triton  X-100-soluble material  in 40%  sucrose. The protein 
concentration of each fraction was determined by bicinchoninic acid assay 
(Pierce Chemical Co., Rockford, IL). 
Western Blot Analysis and Quantitation of the Cellular 
Distribution  of TF 
Fractions collected from the sucrose gradient were diluted twofold in Tri- 
ton X-100-free MES-buffered saline before precipitation with 10% TCA. 
The  precipitates  were  solubilized  in  nonreducing  SDS-PAGE  sample 
buffer at a concentration of 1 mg/ml. A constant amount of protein (5 p.g) 
was separated on 8-16% gradient gels followed by transfer onto Immo- 
bilon P (Millipore Corp., Bedford, MA) using a semidry transblot system 
and buffers according to Kyhse-Anderson  (28). "IF was detected with poly- 
clonal goat anti-TF IgG that had been affinity purified on immobilized TF 
extracellular domain (50). VIIa was detected with mAb FS-13B12 and fac- 
tor X/Xa with mAb F21-4.2, both of which were generated in the labora- 
tory by standard hybridoma technology and which have been screened for 
specific reactivity with purified vitamin K--dependent proteins. TFPI was 
detected by polyclonal rabbit anti-TFPI IgG. Caveolin was detected by 
mAb (anti-22-kD Rous Sarcoma Virus-Src substrate). Bound primary an- 
tibody was detected by appropriate HRP-conjugated secondary antibody 
that was visualized using chemiluminescence reagents from Amersham 
Corp. and exposure of X-Omat AR film (Eastman-Kodak Co., Rochester, 
NY).  To  quantify the  cellular  distribution  of TF  or  TFPI,  a  defined 
amount of purified TF or TFPI was loaded on each gel and transferred to 
membranes that were used for Western blotting. The quantitation was 
based on densitometric analysis of the films using a densitometer and Im- 
ageQuant software (Molecular Dynamics, Sunnyvale, CA). 
Determination of TF Functional Activity in 
Gradient Fractions 
Fractions were diluted in 25 mM MES, 150 mM NaCI, pH 6.5, to give a fi- 
nal concentration of 2.5 p.g/mt of total protein in the assay. TF in the frac- 
tions was assembled with 10 nM VIIa and 200 nM factor X at a final CaCl  2 
concentration of 2 mM at 37°C.  The reaction was quenched with 50 mM 
EDTA after 5-30 min, and product Xa generation was determined with 
chromogenic substrate. TF-dependent generation of Xa was assured by 
control reactions that included  1 mg/ml of the inhibitory anti-TF mAb 
TF9-6B4 that blocks TF function by  >90%  at  the given concentration 
(47). To block TFPI function in the fractions, the diluted fractions were 
preincubated with 50 I~g/ml polyclonal anti-TFPI antibody for 15 rain at 
37°C before the addition of VIIa and factor X. 
Protease Treatment and Trion X-  114 Fractionation  of 
ECV304 Cells 
ECV304 that were grown to confluence for 3 d were detached with 5 mM 
EDTA, washed once in cell buffer, and counted. Cells were >90% viable. 
3 x  106 cells were incubated in 0.5 ml cell buffer containing 0.1% NaN3 with- 
out or with proteases (proteinase K, chymotrypsin, or elastase) at 500 p.g/ml 
for 2 h on ice. After four washes with ice-cold 100 mM Tris, 1 mM EDTA, 
2000  U/ml  aprotinin,  100  p.M  PMSF,  pH  8.1,  cells  were  pelleted  for 
ELISA or fractionated with Triton X-114. Enzymatic cleavage of the GPI 
linkage with 0.5 U of phospholipase C (Boehringer Mannheim Biochemi- 
cals, Indianapolis, IN) was carried out in cell buffer for 15 min at 37°C, fol- 
lowed by one wash with cold wash buffer as above before pelleting of the 
cells. Cell pellets were lysed in I  ml of 1% Triton X-114 in 0.1 M Tris, 10 
mM EDTA, 2000 U/ml aprotinin, and 100 ~M PMSF by incubating with 
repeated mixing on ice for 15 min (3). Debris was removed by centrifuga- 
tion at 14,000 g at 4°C. Phase separation was induced by incubation of the 
cleared detergent lysate for 5 min at 37°C, followed by brief centrifugation 
at  14,000  g  to separate detergent and aqueous phase. The same buffer 
lacking detergent was added, and the extraction was repeated once. The 
detergent pellicle was extracted with acetone, resulting in precipitation of 
the  solubilized  protein  that  was  resuspended  in  nonreducing sample 
buffer. Extracted  proteins from 5  x  105 cells were loaded per lane for 
electrophoresis, transfer, and Western blotting using polyclonal anti-TFPI 
antibody as described above. 
Results 
Downregulation  of TF.VIIa Complex Function on 
Endothelial Cells 
Human endothelial cells in culture express TF in response 
to stimulation with TNFo~ (37). We observed that the spon- 
taneously transformed human endothelial cell line ECV304 
(61) can be induced to express TF after stimulation with 
TNFa, thus providing an abundant cell source for studying 
the regulation of TF function on endothelial cells. By ELISA, 
we determined that unstimulated ECV304 express 42,700 +__ 
14,200 molecules (n =  3) of TF per cell and that the num- 
ber increases to 128,000  ___ 6,000  (n  =  3) on TNFa-stimu- 
lated cells.  Preincubation of intact ECV304 cells with in- 
hibitory anti-TF mAbs before cell lysis blocked >95% of 
TF function, confirming that TF is almost exclusively ex- 
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(12).  In  the  experiments  described,  ECV304  cells  were 
stimulated for 5 h with 10 ng/ml TNF~, and cell surface- 
expressed TF was saturated with the ligand VIIa (10 nM) 
by incubation  for  an  additional  hour  at  4°C.  Unbound 
VIIa was removed by washes with Ca2+-containing buffer 
at 37°C, and factor X was added at the same temperature 
to monitor proteolytic function of the TF.VIIa complexes 
expressed on the cell surface. 
The rate of factor X  activation progressively declined 
with time (Fig. 1), and a 35-60% reduction was consistently 
observed  in  all  experiments  after  a  15-min  reaction. 
TF.VIIa function consistently declined to <50%  after 30 
min, but >80% inhibition, as shown in Fig. 1, was not ob- 
served in all experiments. The decrease of function is not 
attributable  to substrate  depletion,  because  <1%  of the 
initially  present  substrate  was  used  after  30  min.  The 
downregulation  of TF.VIIa function  was  dependent  on 
the presence of substrate, since preincubation in buffer for 
30 min before addition  of substrate resulted  in identical 
initial rates and a  similar decrease in function over time 
(Fig.  1).  This finding excludes the interpretation that the 
loss of cell surface TF.VIIa function is a consequence of 
dissociation or internalization of the complex that may oc- 
cur independent of substrate. 
In control experiments, cells were metabolically inhib- 
ited with 0.1% NaN3 to evaluate the energy dependence of 
the observed reduction in TF.VIIa function. There was no 
difference  between  metabolically  active  and  inhibited 
cells, indicating that the inhibition of function is indepen- 
dent of an energy producing metabolism. TF.VIIa on en- 
dothelial  cells  has  been shown  to activate the  substrate 
factor IX (4).  To test whether  the  decrease  in  TF.VIIa 
function  follows interaction with  any substrate,  ECV304 
were incubated with the substrate factor IX (300 nM) for 
30 min, followed by rapid washes to remove product IXa 
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Figure 1.  Downregulation of TF.VIIa proteolytic function on en- 
dothelial  cells. TNFa-stimulated  ECV304  cells  were  preincu- 
bated with 10 nM VIIa to form the TF-VIIa complex and washed. 
Substrate factor X (5 p~M) was added, and the rate of Xa genera- 
tion was  determined  as  a measure for proteolytic function  of 
TF.VIIa. Proteolytic function  was  rapidly downregulated  ([3). 
Preincubation of the ceils in buffer for 30 min before the addition 
of substrate did not change the initial rate or downregulation  of 
TF-VIIa function (O). Mean and SD of triplicate determinations 
are shown. 
and  remaining  substrate  factor  IX.  Factor  X  was  then 
added to determine TF.VIIa functional activity of the pre- 
treated  cells.  Preincubation  with  factor  IX  neither  de- 
creased the initial rate of factor X activation nor the subse- 
quent decrease in TF.VIIa proteolytic function (data not 
shown). Thus, substrate interaction per se is not sufficient 
to reduce TF.VIIa complex function. These data are con- 
sistent with inhibition of TF.VIIa function specifically de- 
pendent on the conversion of factor X to the product Xa. 
Ultrastructural Localization of TF 
To gain insight into the cellular events associated with the 
downregulation of cell surface TF.VIIa complex function, 
we investigated the cellular distribution  of TF by immu- 
nogold EM. To tag TF, we used a noninhibitory anti-TF 
mAb (TF9-10H10) (50), which neither inhibits VIIa bind- 
ing to TF nor the subsequent assembly of substrate and of 
inhibitors  with  the  TF.VIIa  complex.  This  functionally 
neutral antibody specifically reacts with TF on cells, based 
on  analysis  by immunofluorescence  microscopy demon- 
strating blocking of the staining by addition of a  fivefold 
molar excess of recombinant soluble TF extraceUular domain 
(49).  In initial  experiments, cells were tagged with TF9- 
10H10 IgG and incubated at 37°C in the absence (control) 
or presence of VIIa and substrate factor X for 30 min. Af- 
ter transfer onto ice, the mAb specifically bound to TF was 
reacted with 10-nm gold-conjugated anti-mouse antibody 
followed by fixation for transmission EM. In control reac- 
tions, TF was predominantly detected  on the  cell mem- 
brane and on cellular processes. In the presence of VIIa 
and factor X, gold particles were found more frequently in 
noncoated plasmalemma vesicles with morphological ap- 
pearance and size consistent with caveolae (Fig. 2 a), while 
some TF was still found in both the cell membrane and 
cellular processes. 
To rule out the possibility of nonspecific clustering due 
to secondary antibody cross-linking, monovalent Fab frag- 
ments of TF9-10H10 (51) were generated and conjugated 
to small (<5 nm) gold particles. TF tagged with directly la- 
beled Fab fragments was also found more frequently in ca- 
veolae when VIIa and factor X were added. Vertical thin 
sections were analyzed to quantify the cellular distribution 
of TF. The basal and apical contours of nucleated sections 
were  examined,  and  the  number of gold  particles  were 
counted. Fig. 2 illustrates the locations in which gold parti- 
cles  were  detected.  The most frequent  location  was the 
smooth cell membrane (Fig. 2 e) where clusters of one to 
ten particles were detected. Clusters of one to three parti- 
cles were found  on cellular processes  (Fig.  2  b),  and in 
caveolae clusters  of one  to five gold  particles  were  de- 
tected (Fig. 2, d and e). Gold particles were typically absent 
from clathrin-coated pits that were identified by the char- 
acteristic coat (Fig. 2 c). A  total of 41  sections were ana- 
lyzed for the control and the experimental group, both of 
which  had  similar  numbers  of  caveolae  and  clathrin- 
coated pits (Table I). Whereas <4% of the gold particles 
on the control were found in caveolae, the localization of 
TF in caveolae was increased to 34%  in the presence of 
VIIa and factor X. This percentage of gold particles in cav- 
eolae was consistently obtained by two investigators who 
analyzed the sections according to the given criteria. These 
The Journal of Cell Biology, Volume 133, 1996  296 Figure 2.  Ultrastructural localization of TF by immunogold EM. 
TNFct-stimulated  ECV304 were incubated with VIIa and factor 
X, and TF was tagged by a noninhibitory  mAb (TF9-10H10). (a) 
Indirect  detection  of  TF  using  10-nm  gold--conjugated  anti- 
mouse secondary antibody. TF was localized  on the cell mem- 
brane  (left), on  cellular  processes  (middle),  and  in  caveolae 
(right). (b-e) TF was directly  detected with <5 nm gold conju- 
gated to monovalent Fab fragments of TF9-10H10. Typical local- 
ization of TF on processes (b), the cell membrane (e, left), and ca- 
veolae  (d and  e, right) is  shown.  TF was  usually  absent from 
clathrin-coated  pits (c). Bar, 200 nm. 
data are consistent with the increased localization of TF in 
caveolae suggested by indirect detection of the tagging an- 
tibody. 
Changes of Triton X-IO0 Solubility of TF in the 
Presence of Substrate 
Solubilization  of endothelial  cells with Triton X-100 fol- 
lowed by sucrose gradient centrifugation has been used to 
isolate cellular fractions that are highly enriched in caveo- 
lin and vesicular structures resembling caveolae (31). We 
examined  whether  the  interaction  of factor  X  with  the 
TF.VIIa complex changed the detergent solubility of TF 
that would be expected from a translocation into glycosphin- 
golipid-rich microdomains on the cell surface. ECV304 cells 
were lysed in Triton X-100 and fractionated on a 5-30% su- 
crose gradient by ultracentrifugation (31). Fractions (1.5 ml) 
were collected from the top of the gradient and analyzed 
by Western  blotting for TF.  In controls,  TF was  mostly 
found in the detergent soluble fractions 7 and 8 that had 
been adjusted  to 40%  sucrose  (Fig.  3).  In cells that  had 
been incubated with VIIa and factor X, TF translocated to 
Triton X-100-insoluble fractions floating at ~14-25%  su- 
crose. Based on laser densitometry, the concentration  of 
TF in  the  detergent-insoluble  fractions increased  10-fold 
Table I. Quantitation of the Cellular Distribution of TF by 
Immunogold EM 
Control  Vlla and factor X added 
Number of sections* analyzed  41  41 
Average number of caveolae 
per section  5.9  4.8 
Average number of coated pits 
per section  0.9  1.1 
Gold particles 
Total  342  237 
On cell surface  268 (78%)  121 (51%) 
On cellular processes  61 (l 8%)  34 (14%) 
In caveolae  13 (4%)  81 (34%) 
In clathrin-coated pits  0 (0%)  1 (1%) 
* Vertical nucleated sections of ECV304. 
after addition of VIIa and factor X. This represents a  re- 
distribution of TF, because the total cellular TF, as deter- 
mined from densitometric quantitations, did not change sig- 
nificantly (total TF for separations with no translocation: 
29 ___ 11 ng [n =  6]; with translocation: 36 _  22 ng In =  4]). 
The low density fractions 3-5 contained caveolin that was 
not  detected  in  the  detergent-soluble  material.  TF  thus 
translocates  into fractions that contain essentially all the 
cellular caveolin, consistent with the ultrastructural local- 
ization of TF in caveolae. The Triton X-100-insoluble frac- 
tions also contained VIIa, demonstrating that the TF.VIIa 
complex did  not  dissociate during translocation  (Fig.  3). 
We further detected Xa as a double band, but not the zy- 
mogen precursor factor X  that can be distinguished by its 
larger  size  under  nonreducing  conditions.  This  indicates 
that Xa translocated with TF-VIIa into caveolae. 
Blocking TFPI Abolishes Downregulation 
of TF Function 
One of the major mechanisms regulating proteolytic func- 
tion is inhibition by specific inhibitors. The TF-VIIa com- 
plex is inhibited  by TFPI, a  Kunitz-type inhibitor that is 
known to be expressed by endothelial  cells (1). By anti- 
body inhibition, we tested whether TFPI may be involved 
in the downregulation of TF function on ECV304 cells. In 
the presence of polyclonal anti-TFPI antibodies, the initial 
rates of factor X activation were increased as compared to 
the noninhibited control (Fig. 4). The lower rate in the lat- 
ter  case  may reflect  an  initial  rapid  downregulation  by 
TFPI during the 2-min sampling period that was used to 
determine  the  intial  rates  for the  reaction.  Notably,  the 
rates of factor X  activation in  the presence of anti-TFPI 
antibodies  did  not  decrease  significantly over the  entire 
30-min reaction period (Fig. 4). mAbs to the first or sec- 
ond Kunitz-type domain of TFPI similarly prevented inhi- 
bition of TF-VIIa function. Inhibition of TF.VIIa by TFPI 
thus appears to be responsible for the downregulation of 
TF-dependent proteolytic function. 
Translocation of TF. VIIa Results in the Inhibition 
of Function 
Since the translocation event paralleled the  downregula- 
tion of TF function, we investigated whether TF was func- 
tional  in  both  the  detergent-insoluble  and  -soluble frac- 
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TF,  VIIa, and  Xa  into  low 
density,  detergent-insoluble 
microdomains. Equal amounts 
of protein from each fraction 
were  separated  on  8-16% 
SDS-PAGE  gradient  gels 
and transferred  for Western 
blotting with polyclonal anti- 
body to TF or mAbs to VIIa, 
X/Xa, and caveolin. Fractions 
are  labeled  from the  top  of 
the  sucrose  gradient;  frac- 
tions 7 and 8 contain the Tri- 
ton  X-100-soluble  material 
adjusted  to 40%  sucrose. In 
the  right panel  (+VIIa, X), 
the cells had been incubated 
with VIIa (10 nM) on ice, fol- 
lowed  by  substrate  200  nM 
factor X for 15 min at 37°C. 
The left panel  (no  VIla, X) 
shows  the  control  experi- 
ment that was incubated un- 
der  the  same  conditions  in 
the absence of both VIIa and 
factor X. 
tions.  Fig. 5  a  shows the comparison of sucrose  gradient 
separations of cells that had been incubated with no ligand, 
VIIa alone, or VIIa in the presence of factor X. There was 
no difference between  the experimental  conditions when 
the  recovery of total  protein  from the  gradient  fractions 
was  compared.  In each  case,  ~85-90%  of the  extracted 
proteins were recovered in fraction 7 and 8, whereas frac- 
tions 3, 4, and 5 contained :--3-7% of the total protein in 
the gradient. A  constant amount of protein from each frac- 
tion was loaded per lane for the analysis of TF content by 
Western blotting,  and the densitometric  quantitation  was 
normalized by an internal  standard on each gel (Fig. 5 b, 
upper panel). The distribution  of the total cellular TF was 
0.4- 
=  0.3-  o 
~'~  0.2. 
N  0.1- 
0.0 
;o  ~o  3'0  40 
Time (rain) 
Figure 4.  Effect of antibodies to TFPI on the downregulation of 
TF  function.  The  rate  of Xa  generation  on  TNFct-stimulated 
ECV304 monolayer over time is shown in the absence ([]) or 
presence (0) of 100 ~g/ml inhibitory anti-TFPI polyclonal anti- 
body. Mean and SD of triplicate determinations are given. 
calculated based on the TF concentration in each lane and 
the total protein content of each fraction. In the absence of 
ligand, 97 %  of TF was detergent soluble in fractions 7 and 
8, and <2%  was found in the caveolin-rich fractions 3, 4, 
and 5. Binding of VIIa to TF resulted  in translocation of 
8%  of the total cellular TF from the detergent-soluble  to 
the low density fractions. In the presence of factor X, the 
TF content in the low density fractions increased to a total 
of 58% of the total cellular TF, demonstrating a major re- 
distribution of the receptor. 
Fractions of equal total protein concentration were ana- 
lyzed for TF functional activity. To compensate for poten- 
tial  dissociation  of the TF-VIIa complex during the frac- 
tionation, excess VIIa was added, and the rate of factor X 
activation  was  determined  as  a  measure  for TF activity. 
Control reactions in the presence of high concentrations of 
a  potent inhibitory mAb to TF demonstrated that the ac- 
tivities measured were TF specific and not caused by other 
unrelated  copurifying proteases.  The  highest  TF activity 
was consistently observed in fraction 7, whereas very low 
activity was observed in fraction 8  (Fig. 5 b, lower panel), 
despite  the  immunochemical  detection  of  a  similar  TF 
content in both fractions (Fig. 5 b, upper panel). The latter 
fraction may represent  a  pool of TF with low proteolytic 
activity that has been identified on the cell surface (29). 
The specific activity of TF in the low density fractions 
was also significantly lower than TF activity in fraction 7. 
Moreover, redistribution  of TF into low density fractions 
was not associated with concordant increases of proteolytic 
function in these fractions. Compared to the control in the 
absence of ligand, TF content normalized for total protein 
in fractions 3-5 increased fourfold in the presence of VIIa 
and 19-fold with both VIIa and factor X  present (Fig. 5 b, 
upper panel). This resulted in only a  two- or threefold in- 
crease  in TF activity for the  same  fractions,  respectively 
The Journal of Cell Biology, Volume 133,  1996  298 Figure 5.  TF functional activity in detergent-soluble and -insoluble fractions. TNFct-stimulated ECV304 cells were lysed with Triton 
X-100 and fracionated on density gradient after incubation with no ligand, VIIa alone, or VIIa and substrate factor X. (a) Western blot 
analyses of the fractions for TF, caveolin, and TFPI are shown. (b, upper panel) TF content per 5 ~g of total protein in each fraction was 
determined by laser densitometry, calibrated by internal standard on the blots; (lower panel) the TF functional activity in each fraction 
(normalized to 2.5 ixg/ml total protein) in an experiment representative for four is shown (open bars). The marked difference in func- 
tional activity between fraction 7 and 8 was further confirmed on six randomly chosen gradient separations. Mixing  experiments be- 
tween fraction 7 and 8 further demonstrated additive functional activities  excluding that an inhibitor for TF function accumulated in 
fraction 8. The functional activity in the gradient fractions was further determined in the presence (filled bars) of 50 I~g/ml  inhibitory an- 
tibodies to TFPI that had no effect in fraction 7 and 8 but consistently increased the functional activity in the low density fractions two- 
to threefold. 
(Fig. 5 b, lower panel). When the fractions were incubated 
with blocking anti-TFPI antibodies,  the activity in the low 
density fractions increased two- to threefold, but no change 
in activity was observed in the Triton X-100-soluble frac- 
tions (Fig. 5 b, lower panel). This demonstrates  that only 
TFPI present  in  low density membrane  fractions  is  con- 
tributing to the inhibition of TF function. However, block- 
ing TFPI in the low density fractions did not restore pro- 
teolytic function of TF-VIIa to levels comparable to TF in 
fraction 7, indicating  that  the glycosphingolipid-rich mem- 
brane composition is not favorable for factor X  activation 
and  thus  independently  supports  the  downregulation  of 
TF.VIIa function. 
TFPI Is Localized in Low Density Fractions 
The  antibody  blocking  experiments  indicated  that  low- 
density detergent-insoluble fractions are critical for the in- 
hibition  of TF.VIIa by TFPI.  Consistently,  TFPI was al- 
most exclusively localized in detergent-insoluble  fractions 
under all the experimental  conditions tested (Fig. 5 a), in- 
cluding  cells  which  were  not  stimulated  by  TNFct  (not 
shown).  Based  on densitometric  scans  of Western  blots, 
we estimated that  >80%  of the cellular TFPI was associ- 
ated  with  fractions  3-5  (Fig.  5  a).  Although  heteroge- 
neous, a significant portion of the detected TFPI was >43 
kD,  indicative  of  full-length  TFPI  with  an  intact  third 
Kunitz-type domain and possibly the basic carboxyl termi- 
nus, both of which have been implicated in binding to cell 
surfaces (15, 66). A  minor band of lower molecular weight 
immunoreactive material  was usually detected in the Tri- 
ton X-100-soluble material.  This may represent carboxyl- 
terminal  truncated  TFPI in the degradative pathway that 
is mediated  by the low density lipoprotein  (LDL) recep- 
tor-related protein (65). The almost exclusive presence of 
TFPI  in  Triton  X-100-insoluble  complexes  is  consistent 
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stable  quaternary  complex  formation  in  a  glycosphin- 
golipid-rich microenvironment on cells. 
GPI-linked Binding Sites  for TFPI Are Responsible  for 
Partitioning in Low Density Fractions 
The method for preparation of detergent-insoluble  frac- 
tions can be considered reliable for the localization of pro- 
teins  to  low density  microdomains,  if the  protein  is  ex- 
pressed on external membranes, as in the case of TF. Since 
the binding sites for TFPI are not defined, one needs to con- 
sider a predominant localization of the inhibitor in internal 
membranes that  are  known  to show similar partitioning 
into low density fractions (27). To address this possibility, 
we used the protease sensitivity of TFPI to distinguish be- 
tween external and intracellular pools. We determined by 
ELISA that ECV304 cells have 26 -+ 5 ng TFPI per 107 cells, 
corresponding to 52,000  +_  10,000  molecules/cell (n  =  3). 
By functional assay, we concordantly determined 26  +_- 6 
ng TFPI per 107 cells (n =  4), and from densitometric anal- 
ysis, we estimate ~120,000 molecules per cell, slightly less 
than  the  concentration  of  TF  on  stimulated  ECV304. 
When intact ECV304 cells (>90% viable) were incubated 
on ice with either proteinase K or chymotrypsin, cell-asso- 
ciated TFPI determined by ELISA was reduced by >90% 
(<2.4  ng/107  cells,  below  the  calibration  range  of  the 
ELISA). From these data we conclude that TFPI is almost 
entirely localized on external membranes. 
The almost exclusive partitioning of TFPI into low den- 
sity microdomains suggested a specific binding site with lo- 
calization  to  a  restricted  glycosphingolipid  environment 
on the cell surface. GPI-linked proteins are known to par- 
tition  in  detergent-insoluble  microdomains  (39),  and  we 
considered the possibility that TFPI is selectively bound to 
GPI-linked sites on endothelial cells. GPI-linked proteins 
further partition into the detergent phase, when tempera- 
ture-induced phase separation with Triton X-114 is used to 
fractionate ceils. Fig. 6 demonstrates the recovery of TFPI 
in the detergent phase of a Triton X-114 lysate of ECV304 
cells. Protease treatment virtually removed all TFPI when 
proteinase  K  and  chymotrypsin were  used,  and  elastase 
significantly reduced the higher molecular weight form of 
TFPI. Enzymatic cleavage of the  GPI anchor with phos- 
phatidylinositol-specific phospholipase C  further substan- 
tially reduced TFPI partitioning into the detergent phase 
of Triton X-114. These data suggest that the as yet to be 
defined receptor for TFPI is  GPI linked and localized in 
the glycosphingolipid-rich parts of the external membranes. 
We could not identify antibodies directed to TFPI, VIIa, 
or factor X that are reactive with the proteins after forma- 
tion of the quaternary complex. Ultrastructural analysis, as 
performed for TF, could therefore not be used to substan- 
tiate that each of the reactants in the quaternary complex 
translocate  into  caveolae,  as  defined  by  ultrastructural 
morphology. 
Requirements  for the Translocation of TF into Triton 
X-lOO-insoluble Domains 
We used the change in detergent solubility of TF to char- 
acterize the critical interactions that allow translocation of 
the  receptor  TF  into  low  density  glycosphingolipid-rich 
Figure  6.  Triton  X-114  extraction  of 
TFPI and release of cell surface  TFPI 
by proteases and phospholipase C. The 
Triton X-114 extract of 5 ×  105 cells is 
loaded per lane,  and TFPI is detected 
by Western  blotting  using  polyclonal 
anti-TFPI antibody.  Suspensions of in- 
tact cells were treated at 4°C with 500 
p,g/ml of the indicated  protease or  at 
37°C with 0.5 U  of phosphatidylinosi- 
tol-specific phospholipase C before ex- 
traction with Triton X-114. 
microdomains  (Fig.  7).  The  binding  of  ligand  VIIa in- 
creased TF detergent insolubility only slightly, consistent 
with  the  reported  low affinity for complex formation of 
TF.VIIa with TFPI (7) that is thought to involve the first 
Kunitz-type domain (20). The addition of factor X or 5 nM 
Xa, which is approximatley the concentration of Xa gener- 
ated  during  a  5-10-min  reaction,  effectively  promoted 
translocation into  low density fractions (Fig. 7).  Regard- 
less whether factor X  or Xa was added, Xa was detected, 
suggesting that the generation of product Xa is critical for 
the  translocation  into  the  detergent-insoluble  fractions. 
Although  5  nM  Xa  promoted  the  translocation  of  the 
TF-VIIa complex, no change  in detergent solubility was 
observed when the same concentration of Xa was added in 
the absence of VIIa (Fig. 7). These data suggest that the 
proposed complex formation of Xa with TF alone, which 
was inferred from in vitro experiments with purified com- 
ponents (18), does not support the translocation of TF and 
the cellular inhibition of function. 
The concentration of Xa in the detergent-insoluble frac- 
tions was fourfold lower in the absence of VIIa, as com- 
pared  to the  experiment in  which TF.VIIa translocation 
was observed (Fig. 7). These data indicate that transloca- 
tion of the TF.VIIa complex increases the concentration 
of Xa in the detergent-insoluble fractions, possibly through 
a transient ternary complex formation of TF.VIIa with Xa 
preceding the translocation event. When TFPI is blocked 
by antibody, only traces of Xa are detected in the deter- 
gent-insoluble fractions, and TF translocation is prevented. 
The stable localization of TF in the  different membrane 
environment must then be dependent on the assembly of 
factor Xa with TFPI. Consistently, preventing the assem- 
bly of Xa with TFPI by covalent active site inhibition of Xa 
with  glutamyl-glycyl-arginyl-chloromethyl  ketone  (EGR- 
Xa) abolished translocation. The presented data are con- 
sistent with a  central role of the product protease Xa in 
mediating  quaternary  complex  formation  in  detergent- 
insoluble  microdomains  achieving  downregulation  of the 
TF.VIIa complex through translocation of the receptor TF. 
Discussion 
This study analyzes the regulation of cell surface assembly 
of the coagulation cascade that is triggered by the protease 
receptor TF. We find that TF redistributes into caveolae 
upon binding of VIIa and generation of product Xa, based 
on the following experimental approaches. First, TF in the 
The Journal of Cell Biology, Volume 133, 1996  300 Figure 7.  Requirements for the redistribution  of TF into caveolin-rich  microdomains.  Western blot analysis for TF, factor X/Xa, and 
TFPI of density gradient fractionations  of ECV304. Cells were incubated with VIIa where indicated for 1 h at 4°C, followed by a 15-min 
reaction at 37°C with buffer, 200 nM factor X (X), 5 nM Xa (Xa), or 5 nM Xa inhibited  at the active site with glutamyl-glycyl-arginyl-chlo- 
romethyl ketone (EGR-Xa). Inhibitory polyclonal antibodies to TFPI (a-TFPI)  were included with 200 nM factor X (X) at a concentra- 
tion of 30 ~g/ml. TF content was determined from densitometric scanning of the blots that had equal amounts of protein loaded. Based 
on the total protein in each fraction, the TF distribution  was calculated and shown as the percentage that partitions into fraction 3-5. 
presence of VIIa and  factor X  was  localized  to plasma- 
lemma vesicles by immunogold  EM.  This contrasts with 
the  analysis in  the  absence of ligands  that  demonstrates 
predominant localization of TF on the cell membrane and 
on cellular processes, as previously described for TF (12, 22, 
34). The lack of significant TF staining in caveolae in the 
absence of ligand excludes that antibody-dependent non- 
specific clustering into caveolae (32) is induced by the ex- 
perimental conditions. We observe a ninefold increase of 
TF in plasmalemma vesicles after a  15-rain incubation  of 
the TF.VIIa complex with substrate factor X. These vesi- 
cles have the typical shape and size (60-100 nm) of caveolae. 
Second, we observe a  ligand-dependent change in Tri- 
ton  X-100  solubility  of the  transmembrane  receptor, re- 
sulting in association of TF with caveolin-rich low density 
fractions after separation by sucrose gradient ultracentri- 
fugation. Formation of the complex of TF with the ligand 
protease VIIa changed Triton X-100 solubility only slightly, 
but  a  10-fold  increase  of TF  in  the  detergent-insoluble 
fractions  was  observed  after  a  15-min  incubation  of  the 
TF.VIIa complex with the substrate factor X. As much as 
60% of the total cellular TF redistributed from the deter- 
gent-soluble fractions to the low density fractions enriched 
in caveolin. Thus, independent  lines of evidence support 
receptor translocation  into caveolae as a  consequence  of 
activation of the substrate factor X. 
The translocation of TF is associated with downregula- 
tion  of TF.VIIa proteolytic function.  Antibody blocking 
experiments demonstrated that the inhibition of function 
is mediated by the major inhibitor of the TF pathway, the 
Kunitz-type  inhibitor  TFPI.  TFPI  was  detected  mostly 
(>80%) in Triton X-100-insoluble fractions after density 
gradient  separation.  TFPI is  a  secreted  protein  and  can 
bind to undefined receptors that are inferred from circum- 
stantial  evidence to be heparan  sulfate proteoglycans or 
glycosaminoglycans on endothelial cells (53). The predom- 
inant localization of TFPI in low density fractions indicates 
that the putative binding sites for TFPI on endothelial cells 
have  a  restricted  distribution.  TFPI  can  be  internalized 
through  the  %-macroglobulin  receptor/LDL  receptor- 
related protein mediated targeting to clathrin-coated pits 
in  hepatoma cells (65).  The internalization  and  degrada- 
tion through the LDL receptor-related protein is inhibited 
by  the  receptor-associated  protein  (RAP),  but  RAP 
blocks only a  small percentage of the binding of TFPI to 
hepatoma cells (36). When internalized through the clath- 
rin-coated pits pathway, TFPI should remain Triton X-100 
soluble and, based on the almost complete detergent insol- 
ubility, we thus exclude a stable association of a significant 
portion of the cellular TFPI to the LDL receptor-related 
protein on endothelial cells. 
We show that the predominant binding sites for TFPI on 
endothelial  cells  are  on  external  membranes  and  GPI 
linked. The recovery of GPI-linked proteins in detergent- 
insoluble fractions is a  consequence  of the association of 
the glycolipid anchor with microdomains that are enriched 
in sphingolipids and cholesterol (5, 24, 54, 57). GPI-linked 
proteins have further been shown to be associated with cav- 
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evidence that the partitioning is not simply an artifact of 
detergent  solubilization.  GPI-linked  proteins  partition 
into low density fractions prepared from cells that are de- 
void of caveolae (16, 21), demonstrating that the coat pro- 
vided by caveolin is not required to constitute glycosphin- 
golipid-rich microdomains on the cell membrane. Caveolae 
share  the  specific  lipid  composition  with  these  micro- 
domains, and several studies suggest that the distribution 
of GPI-linked proteins between caveolae and adjacent gly- 
cosphingolipid-rich  microdomains  is  dynamically  regu- 
lated  (32,  40,  56).  The  ultrastructural  localization  of the 
binding sites for TFPI will be of great importance when 
the  receptor will  be identified  and  suitable  reagents  be- 
come available. 
Inhibition by TFPI involves the formation of a quater- 
nary complex with TF, VIIa, and Xa. In addition to TF, we 
find that the ligand protease VIIa, as well as the product 
Xa,  change  detergent  solubility,  providing  evidence  for 
quaternary  TF.VIIa-Xa.TFPI complex formation in  gly- 
cosphingolipid-rich microdomains. TFPI in the absence of 
Xa has been shown to inhibit the TF.VIIa complex, based 
on analyses with purified components or when added ex- 
ogenously to cells expressing TF.VIIa (7). We found that 
the TF content in the Triton X-100--insoluble fractions in- 
creased only two- to fourfold in the presence of VIIa alone, 
whereas 10- to 20-fold increases were observed when fac- 
tor X was present with the TF.VIIa complex. This suggests 
that the inhibition  of TF.VIIa by cell-associated TFPI is 
inefficient in the absence of Xa. The finding also indicates 
that the Ca  2÷ flux in response to VIIa binding to TF (45) is 
not the driving force for redistribution of TF into low den- 
sity microdomains and caveolae. 
Presence of the substrate factor X or the product Xa ef- 
fectively promoted the  change  in  detergent  solubility of 
TF.VIIa, suggesting that not substrate interaction per se, 
but rather the generation of Xa, is essential for the redis- 
tribution  of TF.  Blocking TFPI-Xa interaction  by occu- 
pancy of the catalytic site of Xa with a covalent peptidyl 
inhibitor or by inhibitory anti-TFPI antibodies prevented 
the redistribution  of TF into low density fractions. TF in 
the presence of Xa, but absence of VIIa, changed deter- 
gent solubility insignificantly, demonstrating that the sta- 
ble assembly with TFPI requires the enzyme VIIa bound 
to TF.  These data  emphasize that  each of the  reactants 
that form the quaternary TF.VIIa.Xa.TFPI complex is re- 
quired for stable localization in low density microdomains. 
Notably, in the  absence of VIIa, substantially less Xa is 
bound to TFPI in the low density fractions, indicating that 
no stable TFPI-Xa complex is preformed for the assembly 
with TF.VIIa. These data suggest that a transient complex 
of TF-VIIa with Xa facilitates translocation and associa- 
tion with TFPI in glycosphingolipid-rich microdomains. 
Based on the presented data, we suggest the following 
sequence  of  events  in  the  downregulation  of  TF-VIIa 
function on endothelial cells (Fig. 8). The TF-VIIa com- 
plex has the highest functional activity in an anionic envi- 
ronment  of  the  plasma  membrane.  Transient  assembly 
with Xa greatly facilitates the interaction of the complex 
with the inhibitor TFPI that is bound to a GPI-linked mol- 
ecule localized in glycosphingolipid-rich microdomains of 
the external plasma membrane. One can speculate that the 
quaternary complex assembles in caveolae or, as depicted 
in Fig. 8, that the macromolecular assembly in noncaveo- 
lar glycosphingolipid-rich microdomains triggers translo- 
cation of the  inhibited  complex into caveolae. Although 
the  presented  data  cannot  exclude  that  the  quaternary 
complex dissociates before the ultrastructurally observed 
translocation of TF into caveolae, this is considered likely 
only as a secondary and slow process, because of the tight 
binding of the inhibitor in the presence of Xa (23). 
Based on this study, caveolae are implicated in the regu- 
lation of cell surface proteolysis. This concept is also sup- 
ported by the observation that the urokinase receptor is 
localized in caveolae of tumor ceils (60). The constitutive 
targeting of the urokinase receptor to caveolae, possibly a 
consequence of its GPI anchor (5), imparts to caveolae the 
ability to promote urokinase receptor--dependent plasmin- 
ogen activation leading to pericellular plasmin generation 
and fibrinolysis. We observed that the specific activity of 
Anionic 
Membrane 
Figure  8.  Schematic  model 
for  the  assembly  of  the 
TF.VIIa complex with TFPI 
on  cells. The  activation  of 
factor  X  is  accelerated  by 
binding  of the  substrate  to 
anionic sites on the cell mem- 
brane and the generation of 
Xa supports binding of TFPI 
to TF.VIIa. TFPI is  associ- 
ated with GPI-linked binding 
sites that are located in gly- 
cosphingolipid-rich  micro- 
domains.  Assembly  of 
TF.VIIa.Xa with  TFPI  may 
occur in caveolae or involve 
a  two-step process in which 
the  quaternary  complex 
forms in  microdomains  fol- 
lowed  by  translocation  of 
complex into caveolae, as in- 
dicated in the figure. 
The Journal of Cell Biology, Volume 133, 1996  302 TF  was higher in Triton X-100--soluble fractions  than in 
the low density fractions, even in the presence of inhibi- 
tory antibodies to TFPI. The decreased specific activity of 
TF in the glycosphingolipid-enriched microdomains may, 
in part, result from direct inhibition by sphingolipids that 
have been shown to interfere with enzyme binding to TF 
(10).  Plasmalemma  vesicles  notably lack  anionic binding 
sites (58) to which substrates factor X  and IX can bind via 
their charged amino-termianl ",/-carboxyglutamic acid-rich 
domains. Membrane binding of substrate greatly enhances 
activation by TF.VIIa (26, 51). Hence, TF function will be 
suppressed  by the  lack  of anionic binding sites  for  sub- 
strate in caveolae. Translocation of TF into caveolae and 
expression of urokinase receptor-dependent plasmin gen- 
eration in caveolae thus result in the concordant effect of 
diminishing pericellular fibrin formation by reducing the 
procoagulant activity while supporting fibrinolysis. 
Certain G  protein-coupled receptors have been shown 
to localize to caveolae after ligand interaction (9, 42, 43), 
and the subsequent internalization through caveolae  has 
been proposed as a mechanism for downregulation of re- 
ceptor function (42, 43). Inhibitors that block the internal- 
ization of alkaline phosphatase into caveolae (40) did not 
affect  the  downregulation of TF-VIIa  complex  function 
(not shown). This suggests that internalization of TF through 
a caveolae-dependent pathway is not essential for assem- 
bly with TFPI and the inhibition of function. Caveolin has 
further been demonstrated to interact with Get-subunits in 
their inactive, GDP-bound form (30), suggesting that re- 
ceptor translocation into caveolae downregulates signaling 
through G  protein-coupled  receptors.  It is unclear what 
triggers the translocation of these receptors into caveolae, 
but one may consider the assembly of signaling molecules 
on the cytoplasmic side of the membrane. Our study indi- 
cates  that  extracellular  macromolecular  assemblies  also 
represent an adequate trigger for the redistribution of re- 
ceptors  into  caveolae,  providing  receptor  sequestration 
and downregulation of function. 
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